Skip to content

Comparison of day and night splints in patients with CTS(carpal tunnel syndrome)

Comparison of the effectiveness of carpal tunnel injection of corticosteroids and night splints, with daily splints in patients with carpal tunnel syndrome according to changes in the degree of symptoms based on assessment forms and electrodiagnostic study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221020056249N1
Enrollment
60
Registered
2022-12-11
Start date
2022-12-04
Completion date
Unknown
Last updated
2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carpal Tunnel Syndrome. Carpal tunnel syndrome

Interventions

Intervention 1: Intervention group1: Injection of 40 mg of methylprednisolone is done in an area slightly proximal to the distal fold of the wrist between the palmaris longus and flexor carpi radialis

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 65 Years

Inclusion criteria

Inclusion criteria: 25-64 y/o Patients diagnosed with mild to moderate CTS in electrodiagnostic study.

Exclusion criteria

Exclusion criteria: Pregnancy Diabetes Melitus Hypothyroidism Inflammatory Arthropathy Rheumatoid Arthritis Polyneuropathy Alcoholism Infections Cervical disc pathologies History of past trauma or surgery

Design outcomes

Primary

MeasureTime frame
VAS (visual analog scale) index for pain evaluation. Timepoint: At first and after 6 weeks of splint. Method of measurement: VAS questionaire.;BCTSQ(Boston Carpal Tunnel Questionnaire) index for function evaluation. Timepoint: At first and after 6 weeks of splint. Method of measurement: Boston questionaire.;NCV(nerve conduction velocity) and median nerve Latency in EDX( electrodiagnostic study). Timepoint: At first and after 6 weeks of splint. Method of measurement: Electrodiagnostic study.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactForouzan Akbari

Shiraz University of Medical Sciences

Akbari.forouzan@gmail.com+98 71 3630 5123

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026